Effects of simvastatin on liver and plasma levels of cholesterol, dolichol and ubiquinol in hypercholesterolemic rats.
Increased levels of blood cholesterol are considered as a major factor in the development of atherosclerosis. Simvastatin, a drug which blocks hydroxymethylglutaryl coenzyme A reductase (HMGCoAR), reduces plasma cholesterol and increases HDL-cholesterol in rats fed a hypercholesterolemic diet. Moreover, simvastatin produces a significant decrease of ubiquinol and dolichol in plasma and in liver.
Marinari
U M
UM
Istituto di Patologia Generale, Università di Genova.
Pronzato
M A
MA
Dapino
D
D
Gazzo
P
P
Traverso
N
N
Cottalasso
D
D
Odetti
P
P
D000818:Animals; D002784:Cholesterol / Q000097:blood / Q000378:metabolism*; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D008076:Cholesterol, HDL / Q000097:blood; D004286:Dolichols / Q000097:blood / Q000378:metabolism*; D006937:Hypercholesterolemia / Q000209:etiology / Q000378:metabolism*; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008148:Lovastatin / Q000031:analogs & derivatives* / Q000494:pharmacology; D008315:Malondialdehyde / Q000097:blood; D051381:Rats; D017207:Rats, Sprague-Dawley; D019821:Simvastatin; D014280:Triglycerides / Q000097:blood; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000097:blood / Q000378:metabolism
D002791:Cholesterol, Dietary; D008076:Cholesterol, HDL; D004286:Dolichols; D014280:Triglycerides; D014451:Ubiquinone; D008315:Malondialdehyde; D002784:Cholesterol; D008148:Lovastatin; D019821:Simvastatin; C003741:ubiquinol